Injectable Biologics for the Treatment of Degenerative Disc Disease

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Orthopedics

Background:

• Degenerative disc disease (DDD) is a major cause of spinal pain and disability globally.
• Treating DDD with biologics is challenging due to the intervertebral disc environment.
• Numerous promising therapies for DDD are in early developmental stages.

Purpose of the Study:

• To review the current status of intradiscal biologic therapies for degenerative disc disease.
• To discuss challenges and potential strategies for translating these therapies.
• To provide an overview of promising therapeutic approaches.

Main Methods:

• Review of current literature on intradiscal biologic therapies for DDD.
• Analysis of pre-clinical and clinical trial data for therapeutic proteins and cell-based therapies.
• Evaluation of delivery methods, efficacy, and safety of investigated treatments.

Main Results:

• Systemic delivery of therapeutic agents is limited by adverse events and poor disc penetration.
• Intradiscal delivery of therapeutic proteins shows promise, supported by pre-clinical studies.
• Cell-based therapies for DDD face challenges including unknown mechanisms, detection issues, and mixed efficacy results.

Conclusions:

• Intradiscal biologic therapies offer a potential avenue for treating DDD and associated pain.
• Further research with larger, well-controlled studies is needed to establish efficacy and safety.
• Optimizing patient selection, therapeutic goals, and delivery methods is crucial for successful translation.